- Home
- CLPR vs MAIA Comparison
CLPR vs MAIA Comparison
Compare CLPR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | MAIA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 49.3M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLPR | MAIA |
|---|---|---|
| Price | $3.18 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 57.3K | ★ 1.1M |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.04 | $0.87 |
| 52 Week High | $4.68 | $3.19 |
Technical Indicators
Market Signals| Indicator | CLPR | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 36.42 |
| Support Level | $3.04 | $1.20 |
| Resistance Level | $3.96 | $1.69 |
| Average True Range (ATR) | 0.13 | 0.19 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 30.68 | 10.19 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.